AGT and cardiac hypertrophy: To further confirm that the inhibition of NF-κB is responsible for the protective effects of the CRAMP peptide in pathological cardiac hypertrophy, NF-κB agonist was used together with rCRAMP in AngII or PE treated cardiomyocytes.